Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine

Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine

Abstract This study followed healthcare personnel (HCP) who had completed a primary series of CoronaVac and then received the third and fourth doses of COVID-19 vaccine. The primary objective was to determine the seroconversion rate of neutralizing antibodies against wild-type SARS-CoV-2 and VOCs at...

Full description

Bibliographic Details
Main Authors: Romanee Chaiwarith, Poramed Winichakoon, Parichat Salee, Tavitiya Sudjaritruk, Jiraprapa Wipasa, Kriangkrai Chawansuntati, Saowaluck Yasri, Harit Thongwitokomarn, Kawisara Krasaewes, Sethawut Ruangsirinusorn, Jutarat Praparattanapan, Nuttarika Solai, Khanuengnit Nuket, Darakorn Boonmee, Orapin Chaichana, Oramai Mueangmo, Jutamad Saheng, Worawan Wongjak
Format: Article
Language:English
Published: Nature Portfolio 2023-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-45735-7

Internet

https://doi.org/10.1038/s41598-023-45735-7

Similar Items